Prognostic significance of nutritional markers in metastatic gastric and esophageal adenocarcinoma

Lucy, X.; Taylor, Kenneth W.; Espin‐Garcia, Osvaldo; Anconina, Reut; Suzuki, Chihiro; Allen, Michael J.; Honório, Marta; Bach, Yvonne; Allison, Frances; Chen, Eric X.; Brar, Savtaj; Swallow, Carol J.; Yeung, Jonathan; Darling, Gail; Wong, Rebecca; Kalimuthu, Sangeetha; Jang, Raymond Woo-Jun; Veit-Haibach, Patrick; Elimova, Elena

doi:10.1002/cam4.3604

Cited by 15 publications

(9 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients diagnosed with advanced gastric cancer have a high mortality rate, poor prognosis following surgery, and a low survival rate 26 . However, the predictive ability of existing research and prognostic prediction models is generally limited and cannot fully reflect the patients' disease status, owing to the absence of nutritional status assessment 9–11 . Notably, TYG appears to be associated with the nutritional status of patients.…”

Section: Discussionmentioning

confidence: 99%

“…26 However, the predictive ability of existing research and prognostic prediction models is generally limited and cannot fully reflect the patients' disease status, owing to the absence of nutritional status assessment. [9][10][11] Notably, TYG appears to be associated with the nutritional status of patients. Moreover, a previous study found that TYG is a risk factor for the development of gastric cancer in a health checkup cohort 27 ; however, research on the effect of TYG on the prognosis of patients with gastric cancer who have undergone surgery is lacking.…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, it should be acknowledged that most of these models predominantly rely on TNM staging and fail to comprehensively consider the various patient‐specific factors that may influence disease progression, including their nutritional status 9 . However, an assessment of the nutritional status is crucial for achieving an all‐encompassing, individualized approach to prognostication in patients with gastric cancer 10,11 …”

Section: Introductionmentioning

confidence: 99%

“…9 However, an assessment of the nutritional status is crucial for achieving an all-encompassing, individualized approach to prognostication in patients with gastric cancer. 10,11 The triglyceride glucose (TYG) index is a noninvasive surrogate indicator of insulin resistance [12][13][14] that combines fasting plasma glucose and triglyceride levels. Furthermore, studies have revealed that the TYG index is a predictor for the development of multiple human diseases, including type 2 diabetes mellitus, 15 cardiovascular diseases, and colorectal cancer.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

An analysis of the relationship of triglyceride glucose index with gastric cancer prognosis: A retrospective study

Cai,

Chen,

Lin

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

Aims/IntroductionGastric cancer, one of the most common malignant tumors worldwide, is affected by insulin resistance. The triglyceride glucose (TYG) index is considered a surrogate indicator of insulin resistance; however, its prognostic value in patients with gastric cancer remains obscure. This study aimed to determine whether the TYG index could predict the long‐term prognosis of patients with gastric cancer after radical resection gastrectomy.Materials and MethodsWe retrospectively analyzed patients with gastric cancer who underwent radical resection gastrectomy. The preoperative TYG index was calculated using the patients' laboratory data. Patients were divided into two groups based on a high or low TYG index. We observed overall survival and evaluated the clinical application value of the index using Cox proportional hazards regression to calculate independent parameters. A prediction model was also established.ResultsIn total, 822 patients with gastric cancer were included. The high and low TYG index groups comprised 353 and 469 patients, respectively. The overall survival time was significantly longer in the high‐index group than in the low‐index group. In the multivariate analysis, TYG index, preoperative age, surgical procedure, tumor node metastasis (TNM) stage, N stage, and postoperative complications (all p < 0.01) were considered independent prognostic predictors. Based on the multivariate analysis, the riglyceride glucose (TYG) index hazard ratio was 0.70 (95% confidence interval, 0.54–0.89, p = 0.004).ConclusionsWe established a model with a high clinical application value and clinical practice relevance to predict the prognosis of gastric cancer. In this model, TYG was an independent protective factor for gastric cancer prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

An analysis of the relationship of triglyceride glucose index with gastric cancer prognosis: A retrospective study

Cai,

Chen,

Lin

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…Emerging evidence further suggests that evaluate NRI at baseline and during treatment can not only indicate patients' nutrition status but also provide useful prognostic information ( 51 ). Nevertheless, while meaningful insights are procurable, little is known about the association between NRI, prognosis, and treatment efficacy in breast cancer patients.…”

Section: Discussionmentioning

confidence: 99%

Nutritional Risk Index Predicts Survival in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy

Chen

Kong

et al. 2022

Front. Nutr.

View full text Add to dashboard Cite

Nutritional risk index (NRI) is an index based on ideal body weight that aims to present body weight and serum albumin levels. It has been utilized to discriminate patients at risk of postoperative complications and predict the postoperative outcome of major surgeries. However, this index remains limited for breast cancer patients treated with neoadjuvant chemotherapy (NACT). The research explores the clinical and prognostic significance of NRI in breast cancer patients. This study included 785 breast cancer patients (477 cases received NACT and 308 cases did not) were enrolled in this retrospective study. The optimal NRI cutoff value was evaluated by receiver operating characteristic (ROC) curve, then reclassified as low NRI group (<112) and high NRI group (≥112). The results demonstrated that NRI independently predicted survival on disease-free survival (DFS) and overall survival (OS) by univariate and multivariate Cox regression survival analyses [P = 0.019, hazard ratio (HR): 1.521, 95% CI: 1.071–2.161 and P = 0.004, HR: 1.415, 95% CI: 1.119–1.789; and P = 0.026, HR:1.500, 95% CI: 1.051–2.143 and P < 0.001, HR: 1.547, 95% CI: 1.221–1.959]. According to the optimal cutoff value of NRI, the high NRI value patients had longer mean DFS and OS time in contrast to those with low NRI value patients (63.47 vs. 40.50 months; 71.50 vs. 56.39 months). Furthermore, the results demonstrated that the high NRI score patients had significantly longer mean DFS and OS time than those with low NRI score patients in early-stage breast cancer (χ2 = 9.0510, P = 0.0026 and χ2 = 9.2140, P = 0.0024) and advanced breast cancer (χ2 = 6.2500, P = 0.0124 and χ2 = 5.8880, P = 0.0152). The mean DFS and OS values in patients with high NRI scores were significantly longer in contrast to those with low NRI scores in different molecular subtypes. The common toxicities after NACT were hematologic and gastrointestinal reactions, and the NRI had no statistically significant effects on toxicities, except in nausea (χ2 = 9.2413, P = 0.0024), mouth ulcers (χ2 = 4.8133, P = 0.0282), anemia (χ2 = 8.5441, P = 0.0140), and leukopenia (χ2 = 11.0951, P = 0.0039). NRI serves as a minimally invasive, easily accessible and convenient prognostic tool for evaluating breast cancer prognoses and treatment efficacy, and may help doctors in terms of selecting measures of greater efficiency or appropriateness to better treat breast cancer.

show abstract

Sarcopenia Is a Prognostic Factor of Adverse Effects and Mortality in Patients With Tumour: A Systematic Review and Meta‐Analysis

Zhang,

Zhan

et al. 2024

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

BackgroundThe relationship between sarcopenia and the prognosis of patients with tumours who received radio‐ and/or chemotherapy still needs to be determined. In this study, we aim to investigate the relationship between sarcopenia and adverse effects and mortality in patients with tumours that received radio‐ and/or chemotherapy, stratified by study design, tumour category, the method sarcopenia assessed, treatment options, study location and among other factors.MethodsPubMed, Web of Science and Embase were searched from inception to 15 August 2024, without language restrictions and with a manual search of references for additional articles retrieval. Cohort studies of ≥ 100 patients with tumours that evaluated the association between sarcopenia or muscle mass and the adverse effects or overall survival induced by radio‐ and/or chemotherapy were included.ResultsThirty‐nine studies were included, involving 8966 patients with tumours, including 3383 patients with sarcopenia. The pooled prevalence of sarcopenia in patients with tumours was 0.42 (95% CI 0.36–0.48, p < 0.001) overall. The prevalence of sarcopenia is higher in Oceania patients 0.60 (95% CI 0.28–0.89, p < 0.001), those with reproductive tumour 0.57 (95% CI 0.30–0.83, p < 0.001), and sarcopenia assessed by the lumbar‐skeletal muscle index 0.46 (95% CI 0.39–0.53, p < 0.001) than in other subgroups, but not show significant differences in sex. Sarcopenia was associated with an increased risk of adverse effects in patients who received radio‐ and/or chemotherapy, with a relative risk (RR) of 1.44 (95% CI 1.21–1.71, p < 0.001). Retrospective studies (RR = 1.49; 95% CI 1.24–1.79; p < 0.001), sarcopenia assessed by other methods (RR = 2.98; 95% CI 1.52–5.87; p < 0.001), and patients in Europe (RR = 1.92; 95% CI 1.15–3.22; p = 0.013), received chemoradiotherapy (RR = 1.47; 95% CI 1.23–1.76; p < 0.001), and with head and neck tumours (RR = 1.54; 95% CI 1.17–2.01; p = 0.010) had higher relative risk than other subgroups. Sarcopenia was also associated with reduced overall survival in patients with tumours, with a pooled hazard ratio (HR) of 1.66 (95% CI 1.40–1.96, p < 0.001). Prospective studies (HR = 1.72; 95% CI 0.97–3.07; p = 0.065), sarcopenia assessed by the cervical‐skeletal muscle index (HR = 2.66; 95% CI 1.73–4.09; p < 0.001), and patients in Asia (HR = 1.91; 95% CI 1.50–2.42; p < 0.001), received chemoradiotherapy (HR = 1.85; 95% CI 1.46–2.45; p < 0.001) and with head and neck tumours (HR = 2.35; 95% CI 1.88–2.95; p < 0.001) had higher HR than other subgroups.ConclusionsSarcopenia was associated with a higher risk of adverse effects and mortality in patients with tumours received radio‐ and/or chemotherapy.

show abstract

Prognostic significance of nutritional markers in metastatic gastric and esophageal adenocarcinoma

Abstract: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Cited by 15 publications

References 28 publications

An analysis of the relationship of triglyceride glucose index with gastric cancer prognosis: A retrospective study

An analysis of the relationship of triglyceride glucose index with gastric cancer prognosis: A retrospective study

Nutritional Risk Index Predicts Survival in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy

Sarcopenia Is a Prognostic Factor of Adverse Effects and Mortality in Patients With Tumour: A Systematic Review and Meta‐Analysis

Contact Info

Product

Resources

About